CEL-SCI Corp

$0.25

(as of May 2, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for CEL-SCI Corp

Stock Price

$0.25

Ticker Symbol

CVM

Exchange

NYSE MKT

Industry Information for CEL-SCI Corp

Sector

Healthcare

Industry

Biotechnology

Company Description for CEL-SCI Corp

Website

https://cel-sci.com

Country

USA

Full Time Employees

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Fundamentals for CEL-SCI Corp

Market Capitalization

$21,115,122

EBITDA

$-24,600,264

Dividends per Share

P/E Ratio

Forward P/E Ratio

Earnings per Share

$-0.48

Earnings per Share Estimate Next Year

Profit Margin

Shares Outstanding

84,124,000

Percent Owned by Insiders

2.21%

Percent Owned by Institutions

7.91%

52-Week High

52-Week Low

Technical Indicators for CEL-SCI Corp

50-Day Moving Average

200-Day Moving Average

RSI

45.43

ATR

0.03

Analyst Ratings for CEL-SCI Corp

Strong Buy

Buy

Hold

Sell

Strong Sell

News About CEL-SCI Corp

Jan 8, 2024, 4:32 AM EST

By John Vandermosten, CFA See more.

Dec 22, 2023, 8:00 AM EST

VIENNA, Va., December 22, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments. See more.

Dec 8, 2023, 3:15 AM EST

By John Vandermosten, CFA See more.

Dec 4, 2023, 8:30 AM EST

VIENNA, Va., December 04, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine* (Leukocyte Interleukin, Injection) to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the UK. See more.